AGTR1 and metabolic disease: Previous studies demonstrated that inhibition of the ACE/AngII/AT1 receptor axis attenuate metabolic abnormalities, indicating the ACE/AngII/AT1 receptor arm as a therapeutic strategy for the treatment of metabolic diseases (Feltenberger et al., 2013; Santos et al., 2013a,b; Santos and Simoes, 2014).